HVTN 807

Phase 1, HIV

This study is assessing an experimental vaccine called 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + Alum immunization in combination with an antiretroviral analytical treatment interruption (ATI) in people living with HIV between the ages of 18 to 55. This study is currently enrolling participants.